RAG
ICPT

RIA Advisory Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

RIA Advisory Group’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-63,523
Closed -$703K – 140
2023
Q2 		$703K Buy
63,523
+21,804
+52% +$304K 0.3% 51
2023
Q1 		$560K Buy
+41,719
New +$722K 0.26% 57

Other funds holding ICPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

RIA Advisory Group's ICPT Position: Q3 2023 in Review

RIA Advisory Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 63,523 shares — an estimated $703K sold.

RIA Advisory Group first reported a position in ICPT in Q1 2023 and held it in 2 quarters. The position peaked at $703K in Q2 2023. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

  • RIA Advisory Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • RIA Advisory Group sold 63,523 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $703K.
  • RIA Advisory Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2023 and held it in 2 quarters.
  • RIA Advisory Group's Intercept Pharmaceuticals, Inc. position peaked at $703K in Q2 2023.
  • 146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on RIA Advisory Group's 13F filing for Q3 2023, filed 14 Nov 2023.